Australian Centre for Blood Diseases, Monash University, Alfred Medical Research and Education Precinct, Commercial Road, Melbourne, Australia.
Blood. 2011 Apr 7;117(14):3912-20. doi: 10.1182/blood-2010-08-301523. Epub 2011 Jan 20.
This study evaluated shedding of the platelet collagen receptor, glycoprotein VI (GPVI) in human plasma. Collagen or other ligands induce metalloproteinase-mediated GPVI ectodomain shedding, generating approximately 55-kDa soluble GPVI (sGPVI) and approximately 10-kDa platelet-associated fragments. In the absence of GPVI ligands, coagulation of platelet-rich plasma from healthy persons induced GPVI shedding, independent of added tissue factor, but inhibitable by metalloproteinase inhibitor, GM6001. Factor Xa (FXa) common to intrinsic and tissue factor-mediated coagulation pathways was critical for sGPVI release because (1) shedding was strongly blocked by the FXa-selective inhibitor rivaroxaban but not FIIa (thrombin) inhibitors dabigatran or hirudin; (2) Russell viper venom that directly activates FX generated sGPVI, with complete inhibition by enoxaparin (inhibits FXa and FIIa) but not hirudin; (3) impaired GPVI shedding during coagulation of washed platelets resuspended in FX-depleted plasma was restored by adding purified FX; and (4) purified FXa induced GM6001-inhibitable GPVI shedding from washed platelets. In 29 patients with disseminated intravascular coagulation, mean plasma sGPVI was 53.9 ng/mL (95% confidence interval, 39.9-72.8 ng/mL) compared with 12.5 ng/mL (95% confidence interval, 9.0-17.3 ng/mL) in thrombocytopenic controls (n = 36, P < .0001), and 14.6 ng/mL (95% confidence interval, 7.9-27.1 ng/mL) in healthy subjects (n = 25, P = .002). In conclusion, coagulation-induced GPVI shedding via FXa down-regulates GPVI under procoagulant conditions. FXa inhibitors have an unexpected role in preventing GPVI down-regulation.
本研究评估了血小板胶原受体糖蛋白 VI(GPVI)在人血浆中的脱落情况。胶原或其他配体诱导金属蛋白酶介导的 GPVI 胞外结构域脱落,生成约 55kDa 的可溶性 GPVI(sGPVI)和约 10kDa 的血小板相关片段。在没有 GPVI 配体的情况下,来自健康个体的富含血小板血浆的凝血诱导 GPVI 脱落,独立于添加的组织因子,但可被金属蛋白酶抑制剂 GM6001 抑制。在内在和组织因子介导的凝血途径中共同存在的因子 Xa(FXa)对于 sGPVI 的释放至关重要,因为 (1) 强烈的 sGPVI 释放被 FXa 选择性抑制剂利伐沙班而不是 FIIa(凝血酶)抑制剂达比加群或水蛭素阻断;(2) 直接激活 FX 的响尾蛇毒产生 sGPVI,与依诺肝素(抑制 FXa 和 FIIa)完全抑制但水蛭素不抑制;(3) 在 FX 耗尽的血浆中重悬的洗涤血小板的凝血过程中,GPVI 脱落受损,通过添加纯化的 FX 得到恢复;(4) 纯化的 FXa 诱导从洗涤血小板中 GM6001 抑制的 GPVI 脱落。在 29 例弥漫性血管内凝血患者中,平均血浆 sGPVI 为 53.9ng/mL(95%置信区间,39.9-72.8ng/mL),与血小板减少症对照组(n=36)的 12.5ng/mL(95%置信区间,9.0-17.3ng/mL)相比(P<0.0001),与健康受试者(n=25)的 14.6ng/mL(95%置信区间,7.9-27.1ng/mL)相比(P=0.002)。结论:凝血诱导的 FXa 通过 GPVI 脱落下调促凝条件下的 GPVI。FXa 抑制剂在防止 GPVI 下调方面具有意想不到的作用。